Xconomy: With New Data, Agios Plots Quick Turn into Key Late-Stage Trials
Summary
Since going public last year, the company has increased its value nearly six fold—from $18 per share to $105 as of Friday—and shown early signs that two different drugs might have an impact on a deadly blood cancer known as acute myeloid leukemia, or AML.“The fact that that percentage has remained relatively constant suggests that this is a real effect, that this number is real.” A key yardstick in Phase 1 trials is safety.Stein says investigators haven’t seen any signs tying cardiovascular toxicity to the drug, and that it’s common for patients with AML to develop septic shock because the cancer destroys their immune-boosting white blood cells.It filed papers with the FDA (a so-called investigational new drug application, or IND) to begin its first trial in June 2013, and dosed the first patient in that study two months later.Separately, while Agios looks to start a registrational trial in AML, South San Francisco, CA-based Sunesis Pharmaceuticals {NASDAQ: SNSS) recently finished one with its drug voxarosin.
Classifications
AskAI Classifications
LabelsLinked Companies
